Tag Archives: cystic fibrosis

April, 2015

March, 2015

  • 23 March

    Vertex’s Experimental Cystic Fibrosis Drug Meets Phase 2 Study Goals

    Vertex Pharmaceuticals announced results from a mid-stage study evaluating its experimental cystic fibrosis drug in combination with Kalydeco (ivacaftor). While the company said that its VX-661 in combination with ivacaftor was generally well tolerated and patients receiving the combination saw an increase in the amount of air they could exhale …

  • 18 March

    FDA Approves Expanded Age Range for Vertex’s Kalydeco

    Vertex Pharmaceuticals’ cystic fibrosis (CF) drug is now approved in the US for an expanded group of patients. The company announced that the US Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for use in children ages 2-5 with CF who have one of 10 mutations in the cystic …

  • 17 March

    Respiratory Biotech Pulmatrix to Merge with Ruthigen

    Respiratory biotech Pulmatrix announced an agreement to merge with publicly traded, biopharmaceutical company Ruthigen. The companies have entered into a definitive merger agreement, under which Pulmatrix will become a wholly-owned subsidiary of Ruthigen – which would take the Pulmatrix name and continue Pulmatrix’s work of advancing a new generation of …

January, 2015

  • 5 January

    FDA Expands Approval of Vertex’s Kalydeco

    Pharmaceuticals Incorporated recently announced that US health regulators approved a supplemental new drug application (sNDA) for the use of Kalydeco (ivacaftor) in a new group of cystic fibrosis (CF) patients. The US Food and Drug Administration (FDA) approved the use of Kalydeco in people with CF ages 6 and older …